Literature DB >> 20021286

Radiation countermeasure agents: an update.

Francis Dumont1, Antoine Le Roux, Pierre Bischoff.   

Abstract

IMPORTANCE OF THE FIELD: Ionizing radiation (IR) can produce deleterious effects in living tissues, leading to significant morbidity and a potentially fatal illness affecting various organs dose-dependently. As people may be exposed to IR during cancer radiotherapy or as a result of a radiological/nuclear incident or act of terrorism, the danger of irradiation represents a serious public health problem. At present, however, this problem remains largely impervious to medical management. There is, therefore, a pressing need to develop safe and effective radiation countermeasure (RC) agents to prevent, mitigate or treat the harmful consequences of IR exposure. AREAS COVERED IN THIS REVIEW: Recent advances in the search for RC agents as reflected by the relevant patent literature of the past five years along with peer-reviewed publications are surveyed. WHAT THE READER WILL GAIN: A total of 43 patents, describing approximately 38 chemically diverse compounds with RC potential are analyzed. These include antioxidants capable of scavenging IR-induced free radicals, modulators of cell death signaling or cell cycle progression, cytokines or growth factors promoting tissue repair and inhibitors of inflammatory cytokines. TAKE HOME MESSAGE: Several of these RC candidates appear promising, including at least two that are undergoing evaluation for fast-track clinical development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20021286     DOI: 10.1517/13543770903490429

Source DB:  PubMed          Journal:  Expert Opin Ther Pat        ISSN: 1354-3776            Impact factor:   6.674


  24 in total

1.  Vitamin D protects endothelial cells from irradiation-induced senescence and apoptosis by modulating MAPK/SirT1 axis.

Authors:  F Marampon; G L Gravina; C Festuccia; V M Popov; E A Colapietro; P Sanità; D Musio; F De Felice; A Lenzi; E A Jannini; E Di Cesare; V Tombolini
Journal:  J Endocrinol Invest       Date:  2015-09-03       Impact factor: 4.256

2.  In vitro metabolism and stability of the actinide chelating agent 3,4,3-LI(1,2-HOPO).

Authors:  Taylor A Choi; Anna M Furimsky; Robert Swezey; Deborah I Bunin; Patricia Byrge; Lalitha V Iyer; Polly Y Chang; Rebecca J Abergel
Journal:  J Pharm Sci       Date:  2015-02-27       Impact factor: 3.534

3.  Decreasing the adverse effects of cancer therapy: an NCI Workshop on the preclinical development of radiation injury mitigators/protectors.

Authors:  Julie L Ryan; Sunil Krishnan; Benjamin Movsas; C Norman Coleman; Bhadrasain Vikram; Stephen S Yoo
Journal:  Radiat Res       Date:  2011-09-01       Impact factor: 2.841

Review 4.  Nonhuman primates as models for the discovery and development of radiation countermeasures.

Authors:  Vijay K Singh; Ayodele O Olabisi
Journal:  Expert Opin Drug Discov       Date:  2017-05-05       Impact factor: 6.098

5.  Neuroprotective effect of acute melatonin treatment on hippocampal neurons against irradiation by inhibition of caspase-3.

Authors:  Jianguo Li; Guowei Zhang; Zhuangzhi Meng; Lingzhan Wang; Haiying Liu; Qiang Liu; Batu Buren
Journal:  Exp Ther Med       Date:  2016-03-31       Impact factor: 2.447

Review 6.  Radiation damage to the lung: mitigation by angiotensin-converting enzyme (ACE) inhibitors.

Authors:  Meetha Medhora; Feng Gao; Elizabeth R Jacobs; John E Moulder
Journal:  Respirology       Date:  2012-01       Impact factor: 6.424

7.  Evaluation of the fullerene compound DF-1 as a radiation protector.

Authors:  Aaron P Brown; Eun Joo Chung; Mary Ellen Urick; William P Shield; Anastasia L Sowers; Angela Thetford; Uma T Shankavaram; James B Mitchell; Deborah E Citrin
Journal:  Radiat Oncol       Date:  2010-05-11       Impact factor: 3.481

8.  HemaMax™, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates.

Authors:  Lena A Basile; Dolph Ellefson; Zoya Gluzman-Poltorak; Katiana Junes-Gill; Vernon Mar; Sarita Mendonca; Joseph D Miller; Jamie Tom; Alice Trinh; Timothy K Gallaher
Journal:  PLoS One       Date:  2012-02-24       Impact factor: 3.240

Review 9.  Acute radiation syndrome caused by accidental radiation exposure - therapeutic principles.

Authors:  Harald Dörr; Viktor Meineke
Journal:  BMC Med       Date:  2011-11-25       Impact factor: 8.775

10.  ON01210.Na (Ex-RAD®) mitigates radiation damage through activation of the AKT pathway.

Authors:  Anthony D Kang; Stephen C Cosenza; Marie Bonagura; Manoj Manair; M V Ramana Reddy; E Premkumar Reddy
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.